Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...
EconoTimes

Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology

Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology ...

Moderna to pay $950M to settle dispute with Bucks County's Arbutus Biopharma

The settlement could go as high as $2.25 billion.

Moderna sued for violating patent linked to Pfizer/BioNTech COVID-19 shot

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by ...

AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0

AI revolutionizes pharma manufacturing by enhancing efficiency, quality, and cost-effectiveness. Key opportunities include predictive maintenance, real-time quality control, and supply chain ...

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...